EPSRC logo

Details of Grant 

EPSRC Reference: EP/Z532964/1
Title: EPSRC MediForge Hub: Industry 5.0 Medicines Manufacturing Research Hub
Principal Investigator: Florence, Professor AJ
Other Investigators:
Adjiman, Professor CS Chapman, Professor P Litster, Professor JD
Brown, Dr C Bourne, Professor RA Johnston, Professor BF
Smith, Dr R Jackson, Professor G Galindo, Professor A
Schroeder, Professor SLM Markl, Dr D Nordon, Professor A
Sefcik, Professor J Cardona, Dr J Love, Professor S
Researcher Co-Investigators:
Project Partners:
Applied Materials AstraZeneca Bruker
Cambridge Crystallographic Data Centre Chiesi Pharmaceuticals Clairet Scientific Ltd
CPI DigiM Eli Lilly and Company (International)
F. Hoffmann-La Roche (International) National Manufacturing Inst Scotland Pfizer
Sanofi (International) Siemens Healthineers Takeda Pharmaceuticals International Gmb
Technobis Crystallization Systems UCB ULab Equipment Ltd.
Department: Inst of Pharmacy and Biomedical Sci
Organisation: University of Strathclyde
Scheme: Standard Research TFS
Starts: 01 July 2024 Ends: 30 June 2031 Value (£): 11,895,078
EPSRC Research Topic Classifications:
Artificial Intelligence Carbon Capture & Storage
Design & Testing Technology Drug Formulation & Delivery
EPSRC Industrial Sector Classifications:
Manufacturing Pharmaceuticals and Biotechnology
Related Grants:
Panel History:  
Summary on Grant Application Form
Ensuring access to affordable, safe, and sustainable medicines is imperative. However, the pharmaceutical industry faces significant contemporary challenges to respond to the needs of patients and produce new medicines faster while managing rising healthcare costs, fragile global supply chains and the impacts of climate crisis. Current methods to develop new processes, driven by a commitment to patient safety and quality, exhibit a natural compromise with their inherent inflexibility, inefficiency and protracted pace. The pandemic laid bare the need for agile, flexible, resilient and secure medicine supply chains and climate change and geopolitical uncertainties create further pressures on assuring patient access to affordable, sustainable medicines. Considering the pharmaceutical sector's significant carbon emissions, high resource intensity and waste generation from its operations, prioritising sustainability is of paramount importance to MediForge's industry partners. Accelerating medicine development approaches to match the rapid progress in drug discovery is essential, all the while upholding safety, ensuring the highest medicine quality.

The MediForge Hub, co-created with industry, aims to transform the development and manufacturing of medicines through pioneering an Industry 5.0 manufacturing system for sustainable, resilient and human-centric medicine production. MediForge will address a grand challenge on transforming sustainable Chemistry, Manufacture and Control (CMC) approaches via human-centric cyber-physical infrastructure for Industry 5.0. CMC methodologies play a vital role in the pharmaceutical industry as they ensure medicines are safe and consistent by examining their chemical composition and assuring manufacturing processes and quality control measures guarantee patient safety.

The MediForge Hub will revolutionise CMC approaches through forging medicine development and advanced manufacturing seamlessly with digital technologies and enable the future workforce to realise the goals of Industry 5.0. The Hub aims to: transform our system-wide understanding of molecules to the final product through the development of:

- a novel integrated cyber-physical research infrastructure

- a world-first medicine development and manufacturing data fabric

- a reconfigurable end-to-end manufacturing testbed

This will be delivered through five research platforms, focusing on creating a system of cyber-physical platforms that integrate scale-down processes with various technologies like AI, robotics, and smart sensors (Platform 1). We will create and connect a data fabric that links material properties, process settings and final product attributes, and advanced system-wide models to inform a real-time digital twin of the entire manufacturing process (Platform 2). The real-time digital twin will drive a new flexible and resilient system for manufacturing pharmaceuticals using modular and reconfigurable technology to increase efficiency and adaptability.

Key Findings
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Potential use in non-academic contexts
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Impacts
Description This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Summary
Date Materialised
Sectors submitted by the Researcher
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
Project URL:  
Further Information:  
Organisation Website: http://www.strath.ac.uk